C2i Genomics, Riken Genesis to expand AI-powered whole-genome MRD cancer detection technology across Japan

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

C2i Genomics entered a collaboration agreement March 2 with Riken Genesis Co., Ltd. to bring MRD cancer monitoring to Japan for pharmaceutical and clinical research.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at the Ohio State University Comprehensive Cancer Center is using artificial intelligence to devise new ways of predicting which patients will develop an aggressive and difficult-to-detect form of breast cancer called lobular cancer, which represents one in every 10 breast cancers diagnosed in the United States.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login